A cataract is any opacity of the lens, whether it is a small local opacity or a diffuse general loss of transparency. Sometimes, it can cause a significant reduction in visual acuity or a functional impairment. Cataract is the leading cause of blindness in the world. Cataract surgery is currently the only effective treatment to improve or maintain vision. Inflammation and pain are the most common difficulties associated with cataract surgery. These difficulties often cause significant patient discomfort, delayed recovery and reduced visual outcome. Treatment of inflammation and pain following cataract surgery are commonly managed with anti-inflammatory eye drops that contain steroids and painkillers.
ISV-305 is an eye drop medication being developed to administer the steroid drug, dexamethasone, to treat inflammation and pain following cataract surgery. ISV-305 uses an innovative vehicle that stabilizes the dexamethasone on the surface of the eye for up to 4-6 hours, during which time the active drug is gradually released. The increased time that ISV-305 remains in the eye allows lower concentrations of a drug to be administered over a longer period of time. If licensed, ISV-305 has the potential to improve safety concerns and treatment adherence through reduced dosing regimen in the treatment of inflammation and pain that occurs after a cataract surgery.
Drugs
November 2018
Ranibizumab for proliferative and non-proliferative diabetic retinopathy
Ranibizumab as intravitreal injections is in clinical development for the treatment of diabetic retinopathy in both its proliferative and non-proliferative forms. Diabetic retinopathy, is a disease that affect the retinas and other parts of the inner eye. It is a chronic progressive condition of the retinal blood vessels due to prolonged raised blood glucose. When new blood vessels and scar tissue form on the retina causing bleeding within the eye and loss of vision, it is called proliferative diabetic retinopathy.